Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 19,000 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares in the company, valued at approximately $1,942,917. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Acceleron Pharma Inc (XLRN) traded down $0.10 during trading hours on Friday, reaching $43.91. The company’s stock had a trading volume of 258,500 shares, compared to its average volume of 320,788. Acceleron Pharma Inc has a twelve month low of $23.07 and a twelve month high of $44.80. The stock has a market capitalization of $1,930.00, a P/E ratio of -17.02 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. During the same period last year, the business posted ($0.55) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that Acceleron Pharma Inc will post -2.65 earnings per share for the current fiscal year.
A number of research analysts have recently weighed in on the company. HC Wainwright raised their target price on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Oppenheimer restated a “hold” rating on shares of Acceleron Pharma in a report on Monday, December 11th. Barclays raised their target price on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. ValuEngine lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, Cann restated a “hold” rating on shares of Acceleron Pharma in a report on Monday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $44.56.
Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP increased its position in Acceleron Pharma by 416.3% in the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,352 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Acceleron Pharma by 969.9% in the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 3,288 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Acceleron Pharma in the third quarter worth $225,000. Trexquant Investment LP purchased a new stake in Acceleron Pharma in the third quarter worth $266,000. Finally, PNC Financial Services Group Inc. increased its position in Acceleron Pharma by 57.8% in the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 3,100 shares during the last quarter. 85.70% of the stock is owned by institutional investors and hedge funds.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.